1
|
Milak MS, Proper CJ, Mulhern ST, Parter AL, Kegeles LS, Ogden RT, Mao X, Rodriguez CI, Oquendo MA, Suckow RF, Cooper TB, Keilp JC, Shungu DC, Mann JJ. A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder. Mol Psychiatry 2016; 21:320-7. [PMID: 26283639 PMCID: PMC4758914 DOI: 10.1038/mp.2015.83] [Citation(s) in RCA: 106] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/10/2014] [Revised: 01/29/2015] [Accepted: 03/09/2015] [Indexed: 12/11/2022]
Abstract
The N-methyl-D-aspartate receptor antagonist ketamine can improve major depressive disorder (MDD) within hours. To evaluate the putative role of glutamatergic and GABAergic systems in ketamine's antidepressant action, medial prefrontal cortical (mPFC) levels of glutamate+glutamine (Glx) and γ-aminobutyric acid (GABA) were measured before, during, and after ketamine administration using proton magnetic resonance spectroscopy. Ketamine (0.5 mg kg(-1) intravenously) was administered to 11 depressed patients with MDD. Glx and GABA mPFC responses were measured as ratios relative to unsuppressed voxel tissue water (W) successfully in 8/11 patients. Ten of 11 patients remitted (50% reduction in 24-item Hamilton Depression Rating Scale and total score ⩽10) within 230 min of commencing ketamine. mPFC Glx/W and GABA/W peaked at 37.8%±7.5% and 38.0%±9.1% above baseline in ~26 min. Mean areas under the curve for Glx/W (P=0.025) and GABA/W (P=0.005) increased and correlated (r=0.796; P=0.018). Clinical improvement correlated with 90-min norketamine concentration (df=6, r=-0.78, P=0.023), but no other measures.
Collapse
Affiliation(s)
- Matthew S. Milak
- Molecular Imaging and Neuropathology Division, Department of Psychiatry, Columbia University, College of Physicians and Surgeons
- New York State Psychiatric Institute, Weill Medical College of Cornell University
| | - Caitlin J. Proper
- Molecular Imaging and Neuropathology Division, Department of Psychiatry, Columbia University, College of Physicians and Surgeons
| | - Stephanie T. Mulhern
- Molecular Imaging and Neuropathology Division, Department of Psychiatry, Columbia University, College of Physicians and Surgeons
| | - Amy L. Parter
- Molecular Imaging and Neuropathology Division, Department of Psychiatry, Columbia University, College of Physicians and Surgeons
| | - Lawrence S. Kegeles
- Molecular Imaging and Neuropathology Division, Department of Psychiatry, Columbia University, College of Physicians and Surgeons
- New York State Psychiatric Institute, Weill Medical College of Cornell University
| | - R. Todd Ogden
- Molecular Imaging and Neuropathology Division, Department of Psychiatry, Columbia University, College of Physicians and Surgeons
- Department of Biostatistics, Columbia University, Mailman School of Public Health
- New York State Psychiatric Institute, Weill Medical College of Cornell University
| | - Xiangling Mao
- Department of Radiology, Weill Medical College of Cornell University
| | - Carolyn I. Rodriguez
- Molecular Imaging and Neuropathology Division, Department of Psychiatry, Columbia University, College of Physicians and Surgeons
- New York State Psychiatric Institute, Weill Medical College of Cornell University
| | - Maria A. Oquendo
- Molecular Imaging and Neuropathology Division, Department of Psychiatry, Columbia University, College of Physicians and Surgeons
- New York State Psychiatric Institute, Weill Medical College of Cornell University
| | - Raymond F. Suckow
- New York State Psychiatric Institute, Weill Medical College of Cornell University
- Analytical Psychopharmacology Laboratory, the Nathan S. Kline Institute for Psychiatric Research
| | - Thomas B. Cooper
- New York State Psychiatric Institute, Weill Medical College of Cornell University
- Analytical Psychopharmacology Laboratory, the Nathan S. Kline Institute for Psychiatric Research
| | - John C. Keilp
- Molecular Imaging and Neuropathology Division, Department of Psychiatry, Columbia University, College of Physicians and Surgeons
- New York State Psychiatric Institute, Weill Medical College of Cornell University
| | - Dikoma C. Shungu
- New York State Psychiatric Institute, Weill Medical College of Cornell University
- Department of Radiology, Weill Medical College of Cornell University
| | - J. John Mann
- Molecular Imaging and Neuropathology Division, Department of Psychiatry, Columbia University, College of Physicians and Surgeons
- Department of Radiology, Columbia University, College of Physicians and Surgeons
- New York State Psychiatric Institute, Weill Medical College of Cornell University
| |
Collapse
|
2
|
Langguth B, Landgrebe M, Wittmann M, Kleinjung T, Hajak G. Persistent tinnitus induced by tricyclic antidepressants. J Psychopharmacol 2010; 24:1273-5. [PMID: 19825900 DOI: 10.1177/0269881109106929] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- Berthold Langguth
- Department of Psychiatry, University of Regensburg, Regensburg, Germany, , Multidisciplinary Tinnitus Clinic, University of Regensburg, Regensburg, Germany
| | - Michael Landgrebe
- Department of Psychiatry, University of Regensburg, Regensburg, Germany, Multidisciplinary Tinnitus Clinic, University of Regensburg, Regensburg, Germany
| | - Markus Wittmann
- Department of Psychiatry, University of Regensburg, Regensburg, Germany
| | - Tobias Kleinjung
- Department of Otorhinolaryngology, University of Regensburg, Regensburg, Germany, Multidisciplinary Tinnitus Clinic, University of Regensburg, Regensburg, Germany
| | - Göran Hajak
- Department of Psychiatry, University of Regensburg, Regensburg, Germany
| |
Collapse
|
3
|
Sanchez-Mejia RO, Mucke L. Phospholipase A2 and arachidonic acid in Alzheimer's disease. Biochim Biophys Acta Mol Cell Biol Lipids 2010; 1801:784-90. [PMID: 20553961 DOI: 10.1016/j.bbalip.2010.05.013] [Citation(s) in RCA: 108] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2010] [Revised: 05/19/2010] [Accepted: 05/20/2010] [Indexed: 12/24/2022]
Abstract
Essential fatty acids (EFA) play a critical role in the brain and regulate many of the processes altered in Alzheimer's disease (AD). Technical advances are allowing for the dissection of complex lipid pathways in normal and diseased states. Arachidonic acid (AA) and specific isoforms of phospholipase A(2) (PLA(2)) appear to be critical mediators in amyloid-beta (Abeta)-induced pathogenesis, leading to learning, memory, and behavioral impairments in mouse models of AD. These findings and ongoing research into lipid biology in AD and related disorders promise to reveal new pharmacological targets that may lead to better treatments for these devastating conditions.
Collapse
|
4
|
Abstract
The past decade has seen a steady accumulation of evidence supporting a role for the excitatory amino acid (EAA) neurotransmitter, glutamate, and its receptors in depression and antidepressant activity. To date, evidence has emerged indicating that N-methyl-d-aspartate (NMDA) receptor antagonists, group I metabotropic glutamate receptor (mGluR1 and mGluR5) antagonists, as well as positive modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors have antidepressant-like activity in a variety of preclinical models. Moreover, antidepressant-like activity can be produced not only by drugs modulating the glutamatergic synapse, but also by agents that affect subcellular signaling systems linked to EAA receptors (e.g., nitric oxide synthase). In view of the extensive colocalization of EAA and monoamine markers in nuclei such as the locus coeruleus and dorsal raphe, it is likely that an intimate relationship exists between regulation of monoaminergic and EAA neurotransmission and antidepressant effects. Further, there is also evidence implicating disturbances in glutamate metabolism, NMDA, and mGluR1,5 receptors in depression and suicidality. Finally, recent data indicate that a single intravenous dose of an NMDA receptor antagonist is sufficient to produce sustained relief from depressive symptoms. Taken together with the proposed role of neurotrophic factors in the neuroplastic responses to stressors and antidepressant treatments, these findings represent exciting and novel avenues to both understand depressive symptomatology and develop more effective antidepressants.
Collapse
Affiliation(s)
- Ian A Paul
- Laboratory of Neurobehavioral Pharmacology and Immunology, Division of Neurobiology and Behavior Research, Department of Psychiatry, University of Mississippi Medical Center, Jackson, Mississippi 39216, USA.
| | | |
Collapse
|
5
|
Stewart CA, Reid IC. Antidepressant mechanisms: functional and molecular correlates of excitatory amino acid neurotransmission. Mol Psychiatry 2002; 7 Suppl 1:S15-22. [PMID: 11986991 DOI: 10.1038/sj.mp.4001014] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Specific targeting of the serotonergic and noradrenergic systems for the development of antidepressant compounds has resulted in drugs with more favourable side-effect profiles but essentially no greater efficacy than those compounds discovered more than 40 years ago. Alternative targets are now being considered in the hope that they will have a faster onset of action and be useful for those patients currently unresponsive to conventional treatments. Excitatory amino acid neurotransmission has been attributed various roles in both normal and abnormal brain function. The N-methyl-D-aspartate receptor in particular has long been postulated to play a role in the formation of memories. Major depressive disorder is characterised by alterations in cognitive function, as well as affect. Although there is evidence that early adverse events and stress can have a causal influence on depression, the underlying neurobiology of the disorder is poorly understood. This review will document current evidence for the involvement of excitatory amino acid neurotransmission in the pathophysiology of the affective disorders. The preclinical literature suggests that both electroconvulsive stimulation and antidepressant drugs can affect hippocampal long-term potentiation and the expression of excitatory amino acid receptor subtypes. Exposing animals to stress, including the kind that produces learned helplessness, can also affect synaptic plasticity in the hippocampus. There is clinical evidence that patients with chronic depression have structural brain abnormalities, including hippocampal atrophy, and a preliminary study has shown that an N-methyl-D-aspartate receptor antagonist may have antidepressant efficacy.
Collapse
Affiliation(s)
- C A Stewart
- University of Dundee, Department of Psychiatry, Ninewells Hospital & Medical School, Dundee DD1 9SY, UK.
| | | |
Collapse
|
6
|
Abstract
Although antidepressant treatments produce clear effects on monoaminergic neuronal function, the link between these effects and therapeutic response to treatment is controversial. Previous studies have demonstrated that antagonists of the NMDA receptor-gated calcium ionophore result in antidepressant-like responses in rodents and humans. Likewise, antidepressant treatments produce regionally selective adaptation of the NMDA receptor suggestive of diminished capacity to gate calcium into receptive neurons. Similarly, voltage-dependent calcium channel antagonists have been reported to produce antidepressant-like effects in rodents. A major target of increases in subcellular calcium concentration is nitric oxide synthase (NOS) which liberates NO in response to stimulation. Recently, we have demonstrated that nitric oxide synthase antagonists produced antidepressant-like response in both in vivo preclinical screening procedures and in post-mortem in vitro studies of beta-adrenoceptor density. We propose: 1) that interruption of the Ca(2+)-calmodulin-NOS-guanylyl cyclase subcellular signaling pathway at any point will produce antidepressant-like effects; 2) that the acute actions of antidepressants in preclinical screening procedures are a consequence of their ability to disrupt Ca(2+)-calmodulin-NOS-guanylyl cyclase signaling; 3) that chronic but, not acute treatment with antidepressants results in adaptation of the Ca(2+)-calmodulin-NOS-guanylyl cyclase signaling pathway; 4) that this adaptation is necessary for the achievement of the therapeutic actions of antidepressants and; 5) that major depression is accompanied by an alteration (hyperactivity?) of subcellular Ca(2+) signaling. Copyright 2001 John Wiley & Sons, Ltd.
Collapse
Affiliation(s)
- Ian A Paul
- Department of Psychiatry, University of Mississippi Medical Center, 2500 North State St., Jackson, MS 39216-4505, USA
| |
Collapse
|
7
|
Zahorodna A, Bijak M. An antidepressant-induced decrease in the responsiveness of hippocampal neurons to group I metabotropic glutamate receptor activation. Eur J Pharmacol 1999; 386:173-9. [PMID: 10618467 DOI: 10.1016/s0014-2999(99)00757-8] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Imipramine, a serotonin and noradrenaline uptake inhibitor, is the prototypical tricyclic antidepressant. The effects of imipramine on neuronal responsiveness to the group I glutamate metabotropic (mGlu) receptor agonist (RS)-3,5-dihydroxyphenylglycine (DHPG) were studied ex vivo, in the CA1 area of rat hippocampus, using extracellular and intracellular recording. DHPG increased the population spike amplitude, depolarized CA1 cells and decreased the slow afterhyperpolarization. Imipramine (20 microM) administered acutely in vitro did not change the effect of DHPG on population spikes. Repeated treatment with imipramine (10 mg/kg, twice daily, for 14 days) significantly attenuated the enhancing effect of DHPG (2.5 and 5 microM) on population spikes, as well as the DHPG-induced depolarization and the decrease in the slow afterhyperpolarization. Repeated treatment with imipramine had no effect on passive or active membrane properties of CA1 pyramidal cells. The results of the time-course experiment demonstrated that the imipramine-induced decrease in the responsiveness of CA1 cells to DHPG was apparent after a 7-day treatment; there was a further decrease after 14 days of treatment to a level which was not changed by longer (21-day) administration of imipramine. The attenuation of neuronal responsiveness to DHPG induced by a 14-day treatment was still detectable 7 days after imipramine withdrawal. It is concluded that repeated treatment with imipramine induces a decrease in the responsiveness of rat CA1 hippocampal neurons to group I mGlu receptor activation with a time course which correlates with the delayed onset of the therapeutic effect of antidepressants in humans. This suggests that alterations in mGlu receptors may contribute to antidepressant efficacy.
Collapse
Affiliation(s)
- A Zahorodna
- Department of Physiology, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12, 31-343, Cracow, Poland
| | | |
Collapse
|